Satellos Bioscience Inc. (NASDAQ:MSLE) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Satellos Bioscience Inc. (NASDAQ:MSLE) has been given an average recommendation of “Moderate Buy” by the seven analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $19.75.

A number of research analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Satellos Bioscience in a research note on Friday, August 7th. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Satellos Bioscience in a research report on Monday, August 17th. Finally, Wells Fargo & Company set a $18.00 price objective on Satellos Bioscience in a research note on Thursday, July 9th.

Hedge Funds Weigh In On Satellos Bioscience

A hedge fund recently raised its position in Satellos Bioscience stock. Stonepine Capital Management LLC lifted its position in Satellos Bioscience Inc. (NASDAQ:MSLE) by 391.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 491,624 shares of the company’s stock after buying an additional 391,624 shares during the quarter. Satellos Bioscience comprises approximately 0.0% of Stonepine Capital Management LLC’s holdings, making the stock its 16th biggest position. Stonepine Capital Management LLC owned approximately 2.36% of Satellos Bioscience worth $3,723,291 as of its most recent filing with the Securities and Exchange Commission.

Satellos Bioscience Price Performance

MSLE opened at $8.50 on Monday. Satellos Bioscience has a 12-month low of $5.30 and a 12-month high of $13.39. The stock has a market capitalization of $180.37 million, a PE ratio of -4.43 and a beta of 1.51. The firm’s fifty day moving average price is $9.43 and its 200 day moving average price is $7.98.

Satellos Bioscience (NASDAQ:MSLE) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.18). On average, equities research analysts forecast that Satellos Bioscience will post -1.86 earnings per share for the current fiscal year.

About Satellos Bioscience

Satellos Bioscience Inc is a biotechnology company focused on developing regenerative medicines for conditions involving skeletal muscle damage, degeneration, or impaired repair. The company’s research is based on the role of muscle stem cells, also known as satellite cells, in maintaining and regenerating muscle tissue.

Satellos’ lead product candidate is SAT-3247, an orally administered small-molecule therapy designed to enhance the activation and function of muscle stem cells. The company is evaluating this approach for potential use in diseases characterized by progressive muscle weakness, including Duchenne muscular dystrophy and other muscle disorders.

Satellos Bioscience is headquartered in Vancouver, British Columbia, and is developing its therapies for international pharmaceutical and biotechnology markets.